Want to see IT:FF full AI Analyst Report?
FF Stock Chart & Stats
€8.70
€0.00(0.00%)
At close: 4:00 PM EDT
€8.70
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.86 - €11.90
Previous CloseN/A
Volume31.57K
Average Volume (3M)31.99K
Market Cap
€175.99M
Enterprise Value€309.48
Total Cash (Recent Filing)€36.34M
Total Debt (Recent Filing)€133.82M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.2%
Share Statistics
EPS (TTM)-0.07
Shares Outstanding22,060,125
10 Day Avg. Volume47,356
30 Day Avg. Volume31,987
Financial Highlights & Ratios
PEG Ratio0.96
Price to Book (P/B)1.82
Price to Sales (P/S)0.97
P/FCF Ratio-85.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.90Price Target Upside25.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.42
Revenue Forecast (FY)€260.92M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRevenue growth of 24.6% indicates meaningful demand across the company’s pharmaceutical manufacturing and commercial activities. If sustained, this expanding top line can improve operating scale, support customer relationships, and provide a base for rebuilding profitability over coming quarters.
Resilient Operating Cash FlowOperating cash flow of approximately €32.4M shows that the core business continues to generate substantial cash despite the reported TTM net loss. This supports ongoing operations and provides some internal funding capacity, although the benefit is reduced by limited free cash flow.
Diversified Pharmaceutical ActivitiesThe company combines contract development and manufacturing with pharmaceutical and nutraceutical distribution. These complementary activities create multiple revenue streams and reduce reliance on a single commercial channel, supporting business resilience as customer demand and product mix change.
Bears Say
Profitability CompressionThe shift to a TTM net loss, together with the sharp gross-margin decline, signals materially weaker earnings quality and reduced pricing or cost absorption. Persistent compression would limit reinvestment, weaken returns, and make revenue growth less valuable to shareholders.
Higher LeverageHigher debt alongside lower equity has increased the company’s financial leverage and reduced balance-sheet flexibility. This structure can amplify the effect of continued margin pressure through financing costs and leave fewer resources available for investment or resilience during weaker trading.
Thin, Volatile Free Cash FlowFree cash flow remains small relative to operating cash flow and has been inconsistent across recent years. This suggests that reinvestment and capital needs absorb much of the cash generated by operations, limiting internally funded growth and reducing the cushion against earnings volatility.
FF FAQ
What was Fine Foods & Pharmaceuticals N.T.M. SpA’s price range in the past 12 months?
Fine Foods & Pharmaceuticals N.T.M. SpA lowest stock price was €6.86 and its highest was €11.90 in the past 12 months.
What is Fine Foods & Pharmaceuticals N.T.M. SpA’s market cap?
Fine Foods & Pharmaceuticals N.T.M. SpA’s market cap is €175.99M.
When is Fine Foods & Pharmaceuticals N.T.M. SpA’s upcoming earnings report date?
Fine Foods & Pharmaceuticals N.T.M. SpA’s upcoming earnings report date is Nov 10, 2026 which is in 46 days.
How were Fine Foods & Pharmaceuticals N.T.M. SpA’s earnings last quarter?
Fine Foods & Pharmaceuticals N.T.M. SpA released its earnings results on Sep 08, 2026. The company reported -€0.142 earnings per share for the quarter.
Is Fine Foods & Pharmaceuticals N.T.M. SpA overvalued?
According to Wall Street analysts Fine Foods & Pharmaceuticals N.T.M. SpA’s price is currently Undervalued.
Does Fine Foods & Pharmaceuticals N.T.M. SpA pay dividends?
Fine Foods & Pharmaceuticals N.T.M. SpA pays a Annually dividend of €0.16 which represents an annual dividend yield of 2.2%. See more information on Fine Foods & Pharmaceuticals N.T.M. SpA dividends here
What is Fine Foods & Pharmaceuticals N.T.M. SpA’s EPS estimate?
Fine Foods & Pharmaceuticals N.T.M. SpA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fine Foods & Pharmaceuticals N.T.M. SpA have?
Fine Foods & Pharmaceuticals N.T.M. SpA has 22,060,125 shares outstanding.
What happened to Fine Foods & Pharmaceuticals N.T.M. SpA’s price movement after its last earnings report?
Fine Foods & Pharmaceuticals N.T.M. SpA reported an EPS of -€0.142 in its last earnings report. Following the earnings report the stock price went down -9.443%.
Which hedge fund is a major shareholder of Fine Foods & Pharmaceuticals N.T.M. SpA?
Currently, no hedge funds are holding shares in IT:FF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fine Foods & Pharmaceuticals N.T.M. SpA
Fine Foods & Pharmaceuticals N.T.M. S.p.A. functions as a contract development and manufacturing organization (CDMO), specializing in the creation of various oral solid forms for the pharmaceutical and nutraceutical sectors. Its pharmaceutical offerings include items such as powders, granules, capsules, standard and film-coated tablets, effervescent granules, and hard gelatine capsules. For the nutraceutical market, the company produces soluble, effervescent, and chewable tablets, fast-melting/sublingual tablets, film-coated tablets, and hard gelatine capsules, alongside soluble and effervescent powders and granules. These nutraceutical products are designed to support a wide range of health needs, encompassing areas like probiotics, multivitamins and minerals, immune system function, sleep and relaxation, gastrointestinal and circulatory health, osteoarticular and urinary systems, women's health, beauty, healthy aging, and mental wellbeing. In addition to its core CDMO services, the company also manufactures and sells a diverse array of cosmetic products, covering hair care, skin care, liquid personal hygiene items, oral hygiene products, deodorants, alcohol-based perfumery, bath and shower gels, shampoos and conditioners, shaping waxes, mouthwashes, creams, gels, and toothpastes. Furthermore, they supply medical surgical aids and devices, various antiseptics for intact skin, hand sanitizers, pre-injection solutions, hydroalcoholic surface cleaners, and iodine. Their product line also extends to orthodontic cleaning tablets, disinfectants, and decongestant nasal sprays. Established in 1984, the company is headquartered in Verdellino, Italy.
FF Stock 12 Month Forecast
Average Price Target
€10.90
▲(25.29% Upside)
Technical Analysis
Valsoia SpA
―
Enervit S.p.A.
―
Italian Wine Brands S.p.A.
―
Laboratorio Farmaceutico Erfo SpA
―
NewPrinces S.p.A.
―



